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ABSTRACT
Objective: Describe the development and
psychometric validation of a brief scale (the Sleep
Condition Indicator (SCI)) to evaluate insomnia
disorder in everyday clinical practice.
Design: The SCI was evaluated across five study
samples. Content validity, internal consistency and
concurrent validity were investigated.
Participants: 30 941 individuals (71% female)
completed the SCI along with other descriptive
demographic and clinical information.
Setting: Data acquired on dedicated websites.
Results: The eight-item SCI (concerns about getting
to sleep, remaining asleep, sleep quality, daytime
personal functioning, daytime performance, duration of
sleep problem, nights per week having a sleep problem
and extent troubled by poor sleep) had robust internal
consistency (α≥0.86) and showed convergent validity
with the Pittsburgh Sleep Quality Index and Insomnia
Severity Index. A two-item short-form (SCI-02: nights
per week having a sleep problem, extent troubled by
poor sleep), derived using linear regression modelling,
correlated strongly with the SCI total score (r=0.90).
Conclusions: The SCI has potential as a clinical
screening tool for appraising insomnia symptoms
against Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5) criteria.
INTRODUCTION
Although insomnia is the most common of all
mental health problems,1 it is seldom
adequately assessed and treatment services are
often poor.2 3 This perhaps reﬂects the per-
spective that insomnia is usually a symptom,4
coupled with minimal medical education on
sleep and its disorders.5 However, there are
three reasons why this perspective must now
change. First, insomnia is not merely a
symptom. It has for some time been proposed
as a genuine diagnosis (see Harvey review),6
and recently the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition
(DSM-5) Work Group recognised that the
previous dichotomy of primary versus
secondary insomnia is not evidence based.7 8
Accordingly, DSM-5 now recommends that
‘insomnia disorder’ should be coded “when-
ever diagnostic criteria are met whether or not
there is a co-existing physical, mental or sleep
disorder”.9 Second, insomnia is not necessarily
transient or benign. Once established, it is
remarkably persistent,10 11 constituting a risk
factor for the development of physical and
mental health problems, notably depres-
sion,12–14 as well as adverse effects on quality of
life.15 16 Chronic insomnia is also associated
with high societal cost17 and is, for example, a
robust predictor of work disability.18 Third,
insomnia is treatable. There is a very substan-
tial level 1 evidence-base, evaluating pharma-
cological and cognitive–behavioural therapies
(CBTs),19 20 although the latter are very
seldom available.3 21
Insomnia is ubiquitous,22 so it is important
that clinicians, general practitioners in par-
ticular, have a reliable, valid and brief screen-
ing tool. A wide range of such instruments is a
standard part of patient-centred care,23 for
example, for depression,24 anxiety25 and
Strengths and limitations of this study
▪ Existing instruments used to evaluate insomnia
lack specificity or do not permit assessment
against the latest diagnostic criteria.
▪ This study describes the development and valid-
ation of a new instrument (the Sleep Condition
Indicator (SCI)) for use in everyday clinical
practice.
▪ The SCI is valid, reliable and sensitive to change
in insomnia severity. Its brevity and appealing
visual format permit rapid assessment and inter-
pretation of poor sleep against contemporary
clinical diagnostic criteria.
▪ While we have used large surveys and treatment
evaluation to assess SCI properties, more work
is required to assess predictive validity with ref-
erence to independent clinical evaluation of
insomnia disorder.
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alcohol problems.26 In the insomnia ﬁeld, two scales in
particular are widely used: the Pittsburgh Sleep Quality
Index (PSQI)27 and the Insomnia Severity Index (ISI).28
The PSQI is an established research tool, which has a
cut-off score indicative of sleep disturbance. However, it
lacks speciﬁcity for insomnia. The ISI is very sound psy-
chometrically, and is more speciﬁc and based on DSM-IV
criteria for insomnia. It is used in the main to select
people for clinical trials and as an outcome measure.
In this paper, we present a further measure (the Sleep
Condition Indicator (SCI)) that may have some useful
features. The SCI is informed by the development phase
for DSM-5 insomnia disorder,7 8 coupled with published
research diagnostic criteria29 and recommended quanti-
tative parameters for sleep disturbance.30 In keeping with
DSM-5, the SCI also evaluates associated daytime factors,
which are important drivers of clinical symptoms22 and
should be incorporated in insomnia measurement.15 16 31
In terms of utility, the SCI is brief but versatile. It yields
(1) a dimensional perspective on sleep quality: on an
intuitive, global scale where higher scores represent
better sleep; (2) a visual proﬁle of night-time and
daytime symptoms that the clinician can use in
consultations and (3) indicative cut-off points for
clinically-signiﬁcant insomnia. This paper summarises
the development and evaluation of the SCI across several
studies, and in doing so addresses two major questions.
First, does the SCI have adequate psychometric proper-
ties? Second, is it possible to derive an even briefer, short
form, SCI that has similar psychometric characteristics?
METHODS
Sample characteristics
Data are reported from ﬁve validation studies (total
n=30 941; 71% female) in which SCI items were adminis-
tered. The Great British Sleep Survey (GBSS) was an
open access, web-based survey completed by adults (18
+years) with a UK postcode yielding data on 12 628 par-
ticipants (72% female; mean age=38.7 years (SD=14.5))
between February 2010 and August 2011.32 The GBSS+
was a revision of the GBSS, extended to any valid zip
code worldwide, from May 2011 to March 2012
(n=11 017; 68% female; 42.3 years (16.5)). The TV
sample was obtained in response to a network pro-
gramme (the Food Hospital, Channel 4) on the sleep
beneﬁts of tart cherry juice (n=6876; 76% female,
36.4 years (13.3)). Glasgow Science Centre data (n=256;
56% female, 40.3 years (14.9)) were collected in 2009–
2010 during a study which assessed the relationship
between salivary α-amylase, sleep pressure and diurnal
preference.33 Finally, a randomised controlled trial
(RCT) sample comprised 164 participants (72% female,
48.9 years (13.7)) recruited into a placebo-controlled
evaluation of CBT for insomnia.34 Ethical agreement
concerning the latter two studies is provided in the
source manuscripts. For the open access web surveys,
participation was covered by the site terms.
Across our combined largest samples (GBSS, GBSS+,
TV), women were slightly younger than men (38.5
(14.9) vs 40.1 (14.7) years; t(27 638)=7.94, p<0.0001)
and the great majority was in average or better physical
health (86%) and mental health (82%; 5-point scale: 0
‘very good’, 1 ‘good’, 2 ‘average’, 3 ‘poor’ and 4 ‘very
poor’). Respondents who made some use of prescription
sleeping pills (9.1%) were 7 years older than those who
did not (46.2 (15.1) vs 39.1 (15.1) year, t(20 813)=19.6,
p<.0001) and had a substantially poorer SCI score (8.56
(4.93) vs 15.6 (7.80), t(20 813)=38.8, p<0.0001). Of the
total sample, 18.1% took over-the-counter sleep aids
(OTCs), and more than one-third of those taking sleep-
ing pills also used OTCs.
Design and measurement
This is a psychometric scale development study.
Standard approaches to the appraisal of validity, reliabil-
ity and sensitivity were applied, making appropriate
selection among the available datasets. These methods
and datasets will be introduced in an integrated way in
subsequent sections, so that the research process can be
more clearly expressed and understood.
RESULTS
Development of the SCI
Content validity
An eight-item scale was developed (see appendix) based
on DSM-5 workgroup draft criteria that were available at
the time (in 2010).7 8 At that stage, a consultation
process was underway and draft information was posted
on the American Psychiatric Association website.
Consequently, the SCI items generated comprised two
quantitative items on sleep continuity (item 1, getting to
sleep; item 2, remaining asleep), two qualitative items
on sleep satisfaction/dissatisfaction (item 4, sleep
quality; item 7, troubled or not), two quantitative items
on severity (item 3, nights per week; item 8, duration of
problem) and two qualitative items on attributed
daytime consequences of poor sleep (item 5, effects on
mood, energy or relationships (personal functioning);
item 6, effects on concentration, productivity or ability
to stay awake (daytime performance)).
Validated quantitative criteria for sleep disruption (eg,
31–45 min to fall asleep) served as responses for sleep
continuity items 1 and 2.8 29 30 Items 5 and 6 on
daytime effects were derived by principal components
analysis (PCA; Varimax rotation) of six individual pro-
posed DSM-5 impact areas, using combined datasets
(GBSS, GBSS+, TV, RCT: valid n=29 650). PCA yielded
satisfactory Kaiser-Meyer-Olkin (KMO=0.874) and
Bartlett (p<0.0001) statistics. Iteration converged after
three rotations. A two component model (derived from
inspection of the scree plot and a criterion for asso-
ciated variance ≥10%) explained 75.8% of total vari-
ance, with item loadings ≥0.60. Component 1
(eigenvalue=3.83; 63.8% of variance) comprised ‘mood’
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(loading=0.812), ‘energy’ (0.651) and ‘relationships’
(0.859), and was subsequently named ‘personal func-
tioning’. Component 2 (eigenvalue=0.72; 12.0% of vari-
ance) comprised ‘concentration’ (0.719) and ‘get
through work’ (0.724), and ‘stay awake’ (0.875) may be
regarded as ‘daytime performance’. PCA offered a rela-
tively pure solution, although ‘energy’ also loaded sig-
niﬁcantly on component 2 (0.519).
We then investigated the inter-relationships of our
eight SCI items using the same methodology, but apply-
ing this time a minimum item loading of 0.40, to permit
incorporation of all eight items. PCA with Varimax
Rotation (KMO=0.888; Bartlett, p<0.0001) yielded a two
component solution (66.4% explained variance).
Component 1 (eigenvalue=4.256, 53.2% variance),
named ‘sleep pattern’, comprised items 1, 2, 3, 4 and 8
with factor loading ranging from 0.453 to 0.776.
Component 2 (eigenvalue=1.06, 13.2% variance),
named ‘sleep-related impact’, comprised item 5 (factor
loading 0.886) and item 6 (0.911). Consistent with clin-
ical presentation, concerns about sleep (item 7) loaded
signiﬁcantly and similarly on ‘sleep pattern’ (0.616) and
‘sleep-related impact’ components (0.576).
Response format
Each item was scored on a 5-point scale (0–4), with
lower scores, in the 0–2 range, reﬂecting putative thresh-
old criteria for insomnia disorder (shaded area: see
appendix). The clinician can then see at a glance the
proﬁle of possible concerns. The possible total score
ranges from 0 to 32, with higher values indicative of
better sleep. However, scores can be readily transformed
into a more intuitive 0–10 SCI range, either by dividing
the total by 3.2, or by using an online version with auto-
mated scoring, which is available free of charge (http://
www.sleepio.com/clinic/).
Concurrent validity and association with related domains
Data from the Science Centre sample demonstrated that
the SCI correlates inversely with the PSQI (r=−0.734)
and the ISI (r=−0.793), suggesting measurement proper-
ties consistent with these related measures. There was
also a small but signiﬁcant association of sleep condition
with self-rated physical health (r=0.222), and an associ-
ation also with mental health (r=0.335). Using more spe-
ciﬁc measures, in the Science Centre sample,
correlation of the SCI with symptoms of depression (r=
−0.426) and anxiety (r=−0.400) on the Hospital Anxiety
and Depression Scale35 was modest, and greater than we
observed in our RCT sample (on the Depression Anxiety
Stress Scale36: depression (r=−0.267), anxiety (r=−0.236)
and stress (r=−0.263)).
We have not at this stage tested the discriminant validity
of the SCI against clinical diagnosis of insomnia disorder.
As a ﬁrst step, however, using our Science Centre sample,
we tested the concurrent validity of SCI cut-offs
(score≤16), reﬂecting the minimum criteria for putative
insomnia disorder (see appendix), against published,
validated ISI cut-off scores. We ﬁrst categorised our
sample according to ISI ranges (ISI score=0–14, reﬂect-
ing ‘no insomnia disorder’ (n=228) vs ‘probable insom-
nia disorder’ ISI score=15–28, n=27)) and conducted an
independent t test on SCI total score. The mean SCI
values for the ‘probable insomnia disorder’ category were
10.7 (SD=5.3) vs 22.9 (SD=6.2) for ‘no insomnia disorder’
(t=9.86, p<0.0001). Applying an SCI cut-off ≤16, 89% of
the sample was correctly identiﬁed as having ‘probable
insomnia disorder’ (ISI scores of ≥15), while an SCI
score of >16 correctly identiﬁed 82% of those with ‘no
insomnia disorder’. These ﬁndings provide further evi-
dence of concurrent validity for the SCI and help to
conﬁrm that a score of ≤16 on the SCI seems reasonable
to detect possible insomnia disorder.
Internal consistency
Cronbach’s α for the GBSS sample was strong at 0.857
(range of α-if-item-deleted 0.822–0.860). Replication of
these internal consistency data was obtained from the
GBSS+ sample (α=0.865). The mean corrected item-total
correlation was moderate (r=0.620), indicating a substan-
tial unique variance per item (shared variance=38%).
Sensitivity to change
We have previously reported that the SCI is sensitive as a
measure of treatment outcome.34
Short-form version of the SCI
Although the SCI is brief, in clinical practice ultra short-
form scales are often helpful (eg, generalised anxiety dis-
order (GAD) 2-items).37 Accordingly, we conducted a step-
wise linear regression analysis to determine which subset
of items (independent variables) explained the greatest
proportion of variance in the dependent variable, SCI
total score. A two-item (SCI-02), comprising item 3 ‘how
many nights’ (standardised β=0.515) and item 7 ‘troubled
you in general’ (β=0.491), together predicted 82% of vari-
ance (adjusted R2=0.820) in the full scale SCI (R2
change=0.672 + 0.148; F(227 637)=62 770, p<0.0001). As a
check on the independence of residuals, we computed the
Durbin-Watson statistic, which was found to be 1.80, sug-
gesting no serial correlation. The SCI-02 also correlated
strongly with the SCI score total (r=0.904).
DISCUSSION
A prerequisite to improved insomnia care is the availability
and regular use of reliable and valid insomnia assessment.
Only then can a clinical problem be recognised as distinct
from normal variation, and a persistent problem be differ-
entiated from a transient one. We have reported here the
development and preliminary validation of the SCI, a
DSM-5 compliant, brief screening measure that may be ﬁt
for such purposes. Results indicate that the SCI is intern-
ally consistent, sensitive to change and correlates strongly
with established screening instruments, known to be sensi-
tive to clinical insomnia (PSQI and ISI). PCA revealed a
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two-component solution (66% of the variance), reﬂecting
the underlying complaint of insomnia; that is, concerns
about sleep pattern and concerns about the impact of
poor sleep, both of which need to be addressed in clinical
practice. The derived two-item short-form version, focus-
ing on the severity of the presenting complaint coupled
with frequency of the sleep problem, correlated strongly
with total SCI score and we would suggest that these might
be the lead questions for a clinician to use in the context
of their consulting room practice.
Of course, further work is required, particularly
real-world studies of how the SCI might be used in
population screening and in the evaluation of outcome
following an episode of care. While comparisons with
ISI cut-offs provide evidence of concurrent validity and
indicate that an SCI score ≤16 may help detect probable
insomnia disorder, studies of predictive validity with ref-
erence to independent clinical evaluation of insomnia
disorder (the gold standard) are essential before ﬁrm
conclusions can be made.
It should be noted that over half of the respondents to
our online surveys screened positive for possible insom-
nia disorder. These, of course, are not prevalence data
as we did not adopt a formal population sampling
approach. Nevertheless, the inevitable bias of these
open access surveys towards those with sleep concerns
does permit us (1) to proﬁle many respondents against
criteria; (2) to conduct powerful analyses of the proper-
ties of the SCI and (3) to make comparisons with size-
able cohorts of good sleepers. Importantly, for our
Science Centre sample, approximately 10% scored in
the probable insomnia disorder range (ISI score ≥15),
consistent with prevalence data,2 providing further
support for our ISI–SCI concurrent validity analysis.
Furthermore, a limitation of the SCI is that it does not
contain speciﬁc questions relating to early morning awa-
kenings (EMA; premature awakening with inability to
return to sleep)—a symptom which has recently been
incorporated into DSM-5 criteria. While established
insomnia questionnaires, including the ISI28 and Athens
Insomnia Scale,37 probe perceived severity of EMA,
quantitative values for EMA, to our knowledge, are yet
to be deﬁned. To some extent, SCI item 2 on wakeful-
ness during the night may capture this symptom, com-
plaint, but we recommend that the clinician follows up a
‘positive’ answer to locate the nature and temporal pos-
ition of wakefulness during the sleep period. Moreover,
other core DSM-5 criteria do not feature as SCI items
(eg, the sleep difﬁculty occurs despite adequate oppor-
tunity for sleep; the insomnia is not better explained by
and does not occur exclusively during the course of
another sleep-wake disorder; and the insomnia is not
attributable to the physiological effects of a substance).
However, these items are not easy to probe unambigu-
ously with a self-completed psychometric instrument and
would require careful scrutiny by a treating clinician. It
is, of course, possible that sleep disorders other than
insomnia (eg, circadian rhythm sleep disorders, sleep-
breathing disorders) may also lead to low scores on the
SCI. Thus, the SCI should be viewed as an insomnia
screening tool, consistent with features of DSM-5, but
requiring careful follow-up in clinical practice to fully
deﬁne the nature of sleep disturbance.
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Appendix: The sleep condition indicator
Score
Item 4 3 2 1 0
Thinking about a typical night in the last month …
1. … how long does it take you to fall asleep? 0–15 min 16–30 min 31–45 min 46–60 min ≥61 min
2. … if you then wake up during the night … how long
are you awake for in total? (add all the wakenings up)
0–15 min 16–30 min 31–45 min 46–60 min ≥61 min
3. … how many nights a week do you have a problem
with your sleep?
0–1 2 3 4 5–7
4. … how would you rate your sleep quality? Very good Good Average Poor Very poor
Thinking about the past month, to what extent has poor sleep…
5. … affected your mood, energy, or relationships? Not at all A little Somewhat Much Very much
6. … affected your concentration, productivity, or ability to
stay awake
Not at all A little Somewhat Much Very much
7. … troubled you in general Not at all A little Somewhat Much Very much
Finally …
8. … how long have you had a problem with your sleep? I don’t have a
problem/<1 mo
1–2 mo 3–6 mo 7–12 mo >1 yr
Scoring instructions:
Add the item scores to obtain the SCI total (minimum 0, maximum 32).
A higher score means better sleep.
Scores can be converted to 0–10 format (minimum 0, maximum 10) by dividing total by 3.2.
Item scores in grey area represent threshold criteria for Insomnia Disorder.
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